Review and assessment of pharmacologic management strategies for reflux esophagitis (PDF)
Pharmacologic therapy is the second cornerstone of the medical management of reflux esophagitis. Because the merits of various drug classes for reflux esophagitis have been widely discussed, the focus of this article is on differing strategies for using these classes. The management strategies - and the rationale and evidence for promoting or rejecting them - are discussed for step-up therapy, empiric therapy, ste-down therapy, on-demand proton pump inhibitor use, combination therapies, and other considerations.
During the Health System Executive Summit, Candy Tsourounis, PharmD, and Elise Wozniak, PharmD got candid about the barriers and financial risk surrounding this innovative therapy.
Foundational Pharmacy Strategies’ Christine Johnston on how rebate structures, pending legislation, and a stalled pipeline are reshaping — and threatening — the biosimilar market heading into 2027.
Rex Hoffman, M.D., MBA, of Providence Holy Cross walks through a CMO’s day in a hospital that often runs 85% to 100% full, from safety huddles to discharges.
On average, caregivers want to see their children with ADHD fall asleep 30 minutes faster, but the best sleep treatments average approximately 20 minutes, a new survey study found.
Research findings presented at CHEST meeting show COPD hospital readmission drops with discharge checklists and navigation. Other research suggests targeting readmission prevention efforts on patents discharged to post-acute facilities.
As the pharmacist pipeline tightens, leaders from UC Davis Health, UCSF Health, and Sutter Health say financial sustainability now depends as much on capacity as on cost.
GLP-1 use in adults 65 and older with MASLD was linked to a 45% lower risk of death, and a 28% lower risk of hepatic decompensation, a new Houston Methodist Research Institute study shows.